These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38039117)

  • 1. Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial.
    Zheng Z; Chen H; Cai H; Xu S
    Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):387-395. PubMed ID: 38039117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United States.
    Mudumba R; Chan HH; Cheng YY; Wang CC; Correia L; Ballreich J; Levy J
    Value Health; 2024 Feb; 27(2):153-163. PubMed ID: 38042333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
    Fehm T; Cottone F; Dunton K; André F; Krop I; Park YH; De Laurentiis M; Miyoshi Y; Armstrong A; Borrego MR; Yerushalmi R; Duhoux FP; Takano T; Lu W; Egorov A; Kim SB
    Lancet Oncol; 2024 May; 25(5):614-625. PubMed ID: 38697155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04.
    Zhan M; Huang Z; Xu T; Xu X; Zheng H; Wu F
    Front Public Health; 2023; 11():1049947. PubMed ID: 37457280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness model of trastuzumab deruxtecan as second-line treatment in HER2-positive unresectable and/or metastatic breast cancer in Finland.
    Paulissen JHJ; Seddik AH; Dunton KJ; Livings CJ; van Hulst M; Postma MJ; de Jong LA; Freriks RD
    Eur J Health Econ; 2024 Jun; 25(4):689-699. PubMed ID: 37486557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States.
    Peng Y; Wang L; Peng L; Liu Q; Yi L; Luo X; Li S; Qin S; Wan X; Tan C; Chen G
    Clin Ther; 2023 Oct; 45(10):965-972. PubMed ID: 37537015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA.
    Wang J; Yi Y; Wan X; Zeng X; Peng Y; Tan C
    Adv Ther; 2022 Oct; 39(10):4583-4593. PubMed ID: 35943715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression.
    Huang X; Lin D; Lin S; Luo S; Huang X; Deng Y; Weng X; Huang P
    Clin Breast Cancer; 2023 Jul; 23(5):508-518. PubMed ID: 37085377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer.
    Shi D; Liang X; Li Y; Chen L
    PLoS One; 2023; 18(8):e0290507. PubMed ID: 37616309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
    Modi S; Saura C; Yamashita T; Park YH; Kim SB; Tamura K; Andre F; Iwata H; Ito Y; Tsurutani J; Sohn J; Denduluri N; Perrin C; Aogi K; Tokunaga E; Im SA; Lee KS; Hurvitz SA; Cortes J; Lee C; Chen S; Zhang L; Shahidi J; Yver A; Krop I;
    N Engl J Med; 2020 Feb; 382(7):610-621. PubMed ID: 31825192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis.
    Zhu Y; Liu K; Wang M; Wang K; Zhu H
    Breast; 2022 Dec; 66():191-198. PubMed ID: 36327624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer.
    Yang J; Han J; Zhang Y; Muhetaer M; Chen N; Yan X
    Front Pharmacol; 2022; 13():924126. PubMed ID: 36160459
    [No Abstract]   [Full Text] [Related]  

  • 13. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
    Modi S; Jacot W; Yamashita T; Sohn J; Vidal M; Tokunaga E; Tsurutani J; Ueno NT; Prat A; Chae YS; Lee KS; Niikura N; Park YH; Xu B; Wang X; Gil-Gil M; Li W; Pierga JY; Im SA; Moore HCF; Rugo HS; Yerushalmi R; Zagouri F; Gombos A; Kim SB; Liu Q; Luo T; Saura C; Schmid P; Sun T; Gambhire D; Yung L; Wang Y; Singh J; Vitazka P; Meinhardt G; Harbeck N; Cameron DA;
    N Engl J Med; 2022 Jul; 387(1):9-20. PubMed ID: 35665782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting.
    Hu S; Wu Y; Luan J; Wang S; Fan G
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):17933-17942. PubMed ID: 37964082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer:A meta-analysis of randomized controlled trials.
    Ma R; Shi Y; Yan R; Yin S; Bu H; Huang J
    Crit Rev Oncol Hematol; 2024 Apr; 196():104305. PubMed ID: 38442809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
    Cortés J; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Huang CS; Kim JH; Chiu JWY; Pedrini JL; Lee C; Liu Y; Cathcart J; Bako E; Verma S; Hurvitz SA;
    N Engl J Med; 2022 Mar; 386(12):1143-1154. PubMed ID: 35320644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore.
    Lim EH; Lim A; Khara JS; Cheong J; Fong J; Sivanesan S; Griffiths M; New E; Lee SC
    Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):413-426. PubMed ID: 38289042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis.
    Khoirunnisa SM; Suryanegara FDA; Setiawan D; Postma MJ; de Jong LA
    PLoS One; 2024; 19(5):e0304483. PubMed ID: 38787899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
    Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
    Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
    Hurvitz SA; Hegg R; Chung WP; Im SA; Jacot W; Ganju V; Chiu JWY; Xu B; Hamilton E; Madhusudan S; Iwata H; Altintas S; Henning JW; Curigliano G; Perez-Garcia JM; Kim SB; Petry V; Huang CS; Li W; Frenel JS; Antolin S; Yeo W; Bianchini G; Loi S; Tsurutani J; Egorov A; Liu Y; Cathcart J; Ashfaque S; Cortés J
    Lancet; 2023 Jan; 401(10371):105-117. PubMed ID: 36495879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.